China IVD Market Report 2019: Market is Likely to Exceed the US$ 15 Billion Mark by 2025 - Government Efforts to Regulate Laboratory Testing

DUBLIN, Feb. 21, 2019 /PRNewswire/ -- The "China IVD Market, Share, Trends, Regulations, Reimbursement & Key Players Analysis - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

China In-Vitro Diagnostics (IVD) market is likely to exceed US$ 15 Billion mark by 2025

China is a large and fast-growing in vitro diagnostics (IVD) market - in fact, only second to the United States in terms of value. Historically, large multinational companies have dominated the IVD market in China; today, domestic companies such as Shanghai Kehua Bio-Engineering (KHB) being one of the largest - are now gaining market share.

China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets. China's quickly aging population means the country is experiencing an explosion of chronic conditions such as diabetes, heart disease, and cancer. All of these conditions can be diagnosed and monitored using IVD products. Further, the average Chinese consumer is now willing and able to pay more for healthcare than a decade years ago. Hence, China has the potential for more dramatic growth in the future.

Key Topics Covered:

1. Executive Summary

2. China IVD Market and Market Share Analysis (2009 - 2025)
2.1 China IVD Market and Forecast
2.2 China IVD Market Share and Forecast
2.3 China IVD Company Share and Forecast

3. China IVD - Segments Wise Market and Forecast (2009 - 2025)
3.1 China Clinical Chemistry Market and Forecast
3.2 China Immunoassay Market and Forecast
3.3 China Hematology Market and Forecast
3.4 China Coagulation Market and Forecast
3.5 China Microbiology Market and Forecast
3.6 China Molecular Testing Market and Forecast
3.7 China Self Monitoring of Blood Glucose (SMBG) Market and Forecast
3.8 China Point of Care Testing (POCT) Market and Forecast

4. Development Environment of Chinese IVD Industry
4.1 State Healthcare Reforms
4.2 State Citizen-Benefiting Policies
4.3 Requirements of Hospital Upgrading

5. Profile of In-vitro Diagnostic Reagents Registration Control
5.1 Classification of In-vitro Diagnostic Reagents in China
5.1.1 Class III: Highest Risk
5.1.2 Class II: Medium Risk
5.1.3 Class I: Lower Risk
5.2 Regulatory History in China IVD Market
5.3 Regulatory Status in China IVD Market
5.3.1 Blood Screening Reagents - Drug Administration
5.3.2 Varieties of Blood Screening Reagents
5.3.3 Blood Screening Reagent Test
5.3.4 Nucleic Acid Detection Kits for Blood Screening
5.3.5 Radioactive reagents - Drug Administration
5.3.6 Diagnostic Reagents - Medical Devices Management
5.4 Regulatory Trend in China IVD Market
5.4.1 Blood Screening Reagents Belonging
5.4.2 Quality Improvement
5.4.3 Pre-Evaluation of Registration Standards

6. Registration for In Vitro Diagnostic Reagents in China
6.1 Registration and Filing
6.2 Filing Obligation for Clinical Trials
6.3 Clinical Trial Institutions
6.4 Elimination of IVD Loophole for Research
6.5 Change of Manufacturing Address
6.6 Change of Main Supplier of An Antigen or Antibody
6.7 China In Vitro Diagnostics Registration Update
6.7.1 IVD Product Registration in China
6.7.2 China IVD Type Testing Process
6.7.3 Clinical Trials for IVD Products in China

7. Reimbursement of IVD Products in China

8. China IVD Market - Key Players Sales Analysis (2010 - 2025)
8.1 Roche Diagnostic - China IVD Sales and Forecast
8.2 Abbott Laboratories - China IVD Sales and Forecast
8.3 Sysmex Corporation - China IVD Sales and Forecast
8.4 Mindray Medical International Limited - China IVD Sales and Forecast
8.5 Shanghai Kehua Bio-Engineering Co. Ltd. - China IVD Sales & Forecast
8.6 Others - China IVD Sales and Forecast

9. Profiles of Select Private Clinical Labs and Diagnostic Services Companies
9.1 Dian Diagnostics Group Co. Ltd. (Formerly Zhejiang Di'an Diagnostics Technology Co., Ltd.)
9.1.1 Company Overview
9.1.2 Products and Services Offered by Di'an
9.2 ADICON Clinical Laboratories (Privately held)
9.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
9.4 Kindstar Global (Privately held)
9.5 BGI-Shenzhen
9.6 OriGene Technologies

10. China IVD Industry Drivers
10.1 Government Efforts to Regulate Laboratory testing
10.2 Increasing Number of Private Hospitals & Independent Testing Laboratories
10.3 Chinese Government Policies Encourage Investment in IVD

11. China IVD Industry Challenge
11.1 Lack of Expertise in Advanced Technology in the Local Companies
11.2 Price Pressures Limits the Participation of Multinational IVD Companies in the China IVD Market
11.3 Reimbursement Rates of Different Products Varies in Different Provinces

For more information about this report visit https://www.researchandmarkets.com/research/kcw5zm/china_ivd_market?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets